Trial Profile

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Germ cell cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

09 Jul 2020 Results (n=196) assessing association of neutropenia with disease response to palbociclib in two studies (NCT01037790 & NCT01209598), published in the British Journal of Cancer.
03 Apr 2020 Status changed from recruiting to completed.
20 Aug 2018 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com